$339,98
-$2,59(-0,75 %)
*Data last updated: 2026-04-07 20:04 (UTC+8)
As of 2026-04-07 20:04, Amgen Inc (AMGN) is priced at $339,98, with a total market cap of $182,18B, a P/E ratio of 22,83, and a dividend yield of 2,85 %. Today, the stock price fluctuated between $335,20 and $342,14. The current price is 1,42 % above the day's low and 0,63 % below the day's high, with a trading volume of 507,21K. Over the past 52 weeks, AMGN has traded between $335,20 to $350,02, and the current price is -2,86 % away from the 52-week high.
AMGN Key Stats
Yesterday's Close$342,57
Market Cap$182,18B
Volume507,21K
P/E Ratio22,83
Dividend Yield (TTM)2,85 %
Dividend Amount$2,52
Diluted EPS (TTM)14,30
Net Income (FY)$7,71B
Revenue (FY)$36,74B
Earnings Date2026-05-07
EPS Estimate4,74
Revenue Estimate$8,57B
Shares Outstanding531,82M
Beta (1Y)0.465
Ex-Dividend Date2026-05-15
Dividend Payment Date2026-06-05
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
SectorHealthcare
IndustryDrug Manufacturers - General
CEORobert A. Bradway
HeadquartersThousand Oaks,CA,US
Official Websitehttps://www.amgen.com
Employees (FY)31,50K
Average Revenue (1Y)$1,16M
Net Income per Employee$244,79K
Amgen Inc (AMGN) FAQ
What's the stock price of Amgen Inc (AMGN) today?
x
Amgen Inc (AMGN) is currently trading at $339,98, with a 24h change of -0,75 %. The 52-week trading range is $335,20–$350,02.
What are the 52-week high and low prices for Amgen Inc (AMGN)?
x
What is the price-to-earnings (P/E) ratio of Amgen Inc (AMGN)? What does it indicate?
x
What is the market cap of Amgen Inc (AMGN)?
x
What is the most recent quarterly earnings per share (EPS) for Amgen Inc (AMGN)?
x
Should you buy or sell Amgen Inc (AMGN) now?
x
What factors can affect the stock price of Amgen Inc (AMGN)?
x
How to buy Amgen Inc (AMGN) stock?
x
Risk Warning
The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.
Disclaimer
The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.
